Article PDF
References
Inoue T, Node K : Telmisartan as a metabolic sartan for targeting vascular failure. Expert Opin Pharmacother 2008; 9: 1397–1406.
Grassi G, Quarti-Trevano F, Mancia G : Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. J Renin Angiotensin Aldosterone Syst 2008; 9: 66–74.
TRANSCEND Investigators: Effects of the angiotensinreceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet (in press).
Ohtake T, Oka M, Maesato K, et al: Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis. Hypertens Res 2008; 31: 387–394.
Bakris G, Burgess E, Weir M, et al: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74: 364–369.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakamura, T., Inoue, T. & Node, K. Response to: Telmisartan and Carotid Intima-Media Thickness Regression: A Class Effect of Angiotensin-Receptor Blockers?. Hypertens Res 31, 2188 (2008). https://doi.org/10.1291/hypres.31.2188
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.2188